Compare HASI & ALKS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HASI | ALKS |
|---|---|---|
| Founded | 1981 | 1987 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.1B | 4.5B |
| IPO Year | 2012 | 2012 |
| Metric | HASI | ALKS |
|---|---|---|
| Price | $40.46 | $33.50 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 14 |
| Target Price | ★ $43.57 | $43.43 |
| AVG Volume (30 Days) | 675.4K | ★ 2.6M |
| Earning Date | 05-07-2026 | 04-24-2026 |
| Dividend Yield | ★ 4.18% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | 1.41 | ★ 1.43 |
| Revenue | $400,502,000.00 | ★ $1,475,899,000.00 |
| Revenue This Year | $394.10 | $24.26 |
| Revenue Next Year | $11.64 | $4.47 |
| P/E Ratio | $28.96 | ★ $23.86 |
| Revenue Growth | ★ 4.41 | N/A |
| 52 Week Low | $24.19 | $25.17 |
| 52 Week High | $41.15 | $36.48 |
| Indicator | HASI | ALKS |
|---|---|---|
| Relative Strength Index (RSI) | 69.12 | 55.05 |
| Support Level | $35.18 | $27.65 |
| Resistance Level | N/A | $33.88 |
| Average True Range (ATR) | 0.90 | 1.17 |
| MACD | 0.25 | -0.01 |
| Stochastic Oscillator | 77.37 | 25.69 |
HA Sustainable Infrastructure Capital Inc is an investor in sustainable infrastructure assets advancing the energy transition. Its investment is focused on actively partnering with clients to deploy capital in income-generating real assets that are supported by long-term recurring cash flows. This enabled to the generation of attractive risk-adjusted returns and provided stockholders with diversified exposure to the energy transition. The company's single reportable segment generates net investment and equity method investment income through investments in energy transition assets and infrastructure projects, as well as revenue through the gain on sale of assets and recurring asset management fees.
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.